

Applicants : Maureen J. Charron and Ellen B. Katz
Serial No. : 09/886,954
Filed : June 21, 2001
Page 2

Amendments to the Claims:

Please cancel claims 21-35 without disclaimer to prejudice to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application.

Please amend claims 1 and 11 as indicated below. Additions to the text are indicated by underlining; there are no deletions.

A1
21/0
B2

1. (Currently Amended) A method for determining whether a subject has a defect in cell proliferation, comprising assaying a diagnostic sample of the subject for GLUTx expression, wherein detection of GLUTx expression elevated above normal is diagnostic of a defect in cell proliferation and wherein GLUTx protein comprises the amino acid sequence set forth in Genbank accession number XP_011828.

2. (Original) The method of Claim 1, wherein the defect in cell proliferation is a neoplasm or a pre-neoplastic lesion.

3. (Original) The method of Claim 2, wherein the neoplasm is an adenocarcinoma.

4. (Original) The method of Claim 1, wherein the diagnostic sample is assayed using an agent reactive with GLUTx.

5. (Original) The method of Claim 4, wherein the agent is labeled with a detectable marker.

6. (Original) The method of Claim 4, wherein the agent is an antibody.

Applicants : Maureen J. Charron and Ellen B. Katz
Serial No. : 09/886,954
Filed : June 21, 2001
Page 3

7. (Original) The method of Claim 6, wherein the antibody is labeled with a detectable marker.

8. (Original) The method of Claim 1, wherein the diagnostic sample is assayed using at least one nucleic acid probe which hybridizes to nucleic acid encoding GLUTx.

9. (Original) The method of Claim 8, wherein the nucleic acid probe is DNA or RNA.

10. (Original) The method of Claim 9, wherein the nucleic acid probe is labeled with a detectable marker.

A²
on B²⁷

11. (Currently Amended) A method for assessing the efficacy of therapy to treat a defect in cell proliferation in a subject who has undergone or is undergoing treatment for a defect in cell proliferation, comprising assaying a diagnostic sample of the subject for GLUTx expression, wherein detection of GLUTx expression elevated above normal in the diagnostic sample is indicative of a need to continue therapy to treat the defect in cell proliferation, and normal GLUTx expression in the diagnostic sample is indicative of successful therapy, and wherein GLUTx protein comprises the amino acid sequence set forth in Genbank accession number XP_011828.

12. (Original) The method of Claim 11, wherein the defect in cell proliferation is a neoplasm or a pre-neoplastic lesion.

13. (Original) The method of Claim 12, wherein the neoplasm is an adenocarcinoma.

Applicants : Maureen J. Charron and Ellen B. Katz
Serial No. : 09/886,954
Filed : June 21, 2001
Page 4

14. (Original) The method of Claim 11, wherein the diagnostic sample is assayed using an agent reactive with GLUTx.

15. (Original) The method of Claim 14, wherein the agent is labeled with a detectable marker.

16. (Original) The method of Claim 14, wherein the agent is an antibody.

17. (Original) The method of Claim 16, wherein the antibody is labeled with a detectable marker.

18. (Original) The method of Claim 11, wherein the diagnostic sample is assayed using at least one nucleic acid probe which hybridizes to nucleic acid encoding GLUTx.

19. (Original) The method of Claim 18, wherein the nucleic acid probe is DNA or RNA.

20. (Original) The method of Claim 19, wherein the nucleic acid probe is labeled with a detectable marker.

21.-35. (Canceled)